Back to Search
Start Over
B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
- Source :
-
EBioMedicine [EBioMedicine] 2021 Aug; Vol. 70, pp. 103539. Date of Electronic Publication: 2021 Aug 12. - Publication Year :
- 2021
-
Abstract
- Background: In recent months numerous health care professional acquired COVID-19 at the workplace resulting in significant shortages in medical and nursing staff. We investigated how prior COVID-19 affects SARS-CoV-2 vaccination and how such knowledge could facilitate frugal vaccination strategies.<br />Methods: In a cohort of 41 healthcare professionals with (n=14) and without (n=27) previous SARS-CoV-2 infection, we assessed the immune status before, during and after vaccination with BNT162b2. The humoral immune response was assessed by receptor binding domain ELISA and different SARS-CoV-2 neutralisation assays using wildtype and pseudo-typed viruses. T cell immunity against SARS-CoV-2 surface and nucleocapsid peptides were studied using interferon-γ release assays and intracellular flow cytometry. Vaccine-related side effects were captured.<br />Findings: Prior COVID-19 resulted in improved vaccine responses both in the B and T cell compartment. In vaccine recipients with prior COVID-19, the first vaccine dose induced high antibody concentrations comparable to seronegative vaccine recipients after two injections. This translated into more efficient neutralisation of virus particles, even more pronounced than expected from the RBD ELISA results. Furthermore, T cell responses were stronger in convalescents and particularly strong against the SARS-CoV-2 nucleocapsid protein.<br />Interpretation: Herein, we corroborate recent findings suggesting that in convalescents a single vaccine dose is sufficient to boost adequate in vitro neutralisation of SARS-CoV-2 and therefore may be sufficient to induce adequate protection against severe COVID-19. New spike mutated virus variants render the highly conserved nucleocapsid protein - eliciting strong SARS-CoV-2 specific T cell immunity - an interesting additional vaccine target.<br />Funding: Christian Doppler Research Association, Johannes Kepler University Linz.<br />Competing Interests: Declaration of Competing Interest TRK and MF are employees of Baxter AG, Vienna, Austria, now part of the Takeda group of companies and have Takeda stock interest. All other authors declare no competing interests.<br /> (Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
- Subjects :
- Adult
Antibodies, Neutralizing immunology
Antibodies, Viral immunology
BNT162 Vaccine
COVID-19 virology
Enzyme-Linked Immunosorbent Assay methods
Female
Health Personnel
Humans
Immunity, Humoral immunology
Male
Spike Glycoprotein, Coronavirus immunology
Vaccination methods
B-Lymphocytes immunology
COVID-19 immunology
COVID-19 Vaccines immunology
SARS-CoV-2 immunology
T-Lymphocytes immunology
Subjects
Details
- Language :
- English
- ISSN :
- 2352-3964
- Volume :
- 70
- Database :
- MEDLINE
- Journal :
- EBioMedicine
- Publication Type :
- Academic Journal
- Accession number :
- 34391087
- Full Text :
- https://doi.org/10.1016/j.ebiom.2021.103539